Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital (as of June 30, 2011): 5,604,229,794 Ordinary shares of 25p each.
- Treasury Shares: 469,174,284 Ordinary shares.
- Total Voting Rights: 5,135,055,510.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a statutory notification of current capital structure rather than a comparative financial performance report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Investor Verification Checklist
- Verify the total number of voting rights (5,135,055,510) to determine notification thresholds under Financial Services Authority rules.
- Confirm the number of shares held in Treasury (469,174,284) when calculating outstanding share counts.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for revenue and profit metrics.